Analytical Data
-
Gene name
MNDA
- Application
-
Alternative Names
PYHIN3
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P41218
-
Expression Region
Thr189~Asn405
-
Molecular Weight
28kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of MNDA (myeloid differentiation primary response gene 88) recombinant proteins has gained significant attention due to their crucial role in immune system regulation. MNDA is a pivotal molecule involved in innate immunity, particularly in myeloid cells, where it influences the signaling pathways of various cytokines and plays a role in the modulation of inflammatory responses. Recent research has highlighted that MNDA is not only essential for the maturation of immune cells but also contributes to the body's defense against infections and tumors. In the context of cancer immunotherapy, understanding the structure and function of MNDA can pave the way for novel therapeutic strategies. Additionally, by utilizing recombinant DNA technology, researchers can produce MNDA proteins in sufficient quantities for detailed studies, enabling the exploration of their functional domains and interaction with other signaling molecules. The implications of MNDA research extend to the development of biomarker applications for disease diagnosis and prognosis, particularly in hematological malignancies. Furthermore, identifying the precise mechanisms by which MNDA mediates immune responses could lead to breakthroughs in modulating immune activity, highlighting its potential as a target for drug development. Collectively, this research not only enhances our understanding of the functional diversity of immune components but also marks a significant step toward innovative approaches in treating immune-related diseases.
